|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
75,280,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
22,229 |
48,805 |
236,705 |
576,095 |
Total Sell Value |
$1,027,488 |
$2,098,369 |
$9,481,770 |
$22,449,223 |
Total People Sold |
3 |
4 |
7 |
10 |
Total Sell Transactions |
3 |
6 |
11 |
22 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Holler Frank A |
Director |
|
2016-08-18 |
4 |
S |
$7.70 |
$73,912 |
D/D |
(9,599) |
157,807 |
|
- |
|
Holler Frank A |
Director |
|
2016-08-17 |
4 |
S |
$7.89 |
$12,624 |
D/D |
(1,600) |
167,406 |
|
- |
|
Holler Frank A |
Director |
|
2016-08-16 |
4 |
S |
$8.25 |
$56,620 |
D/D |
(6,863) |
169,006 |
|
- |
|
Pimstone Simon N. |
President & CEO |
|
2016-07-29 |
4 |
D |
$7.46 |
$35,084 |
D/D |
(4,703) |
211,847 |
|
- |
|
Pimstone Simon N. |
President & CEO |
|
2016-07-29 |
4 |
OE |
$3.30 |
$40,739 |
D/D |
12,345 |
216,550 |
|
- |
|
Mortimer Ian |
CFO & COO |
|
2016-06-24 |
4 |
B |
$6.10 |
$26,790 |
I/I |
4,300 |
4,300 |
1.99 |
- |
|
Mortimer Ian |
CFO & COO |
|
2016-06-24 |
4 |
B |
$6.15 |
$6,150 |
D/D |
1,000 |
1,000 |
2.74 |
- |
|
Hayden Michael R |
Director |
|
2016-05-25 |
4 |
OE |
$3.30 |
$27,159 |
I/I |
8,230 |
18,518 |
|
- |
|
Tarnow Michael M |
Director |
|
2016-04-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,543 |
55,167 |
|
- |
|
Tarnow Michael M |
Director |
|
2016-04-28 |
4 |
OE |
$3.35 |
$5,169 |
D/D |
1,543 |
56,710 |
|
- |
|
Robin Sherrington |
SVP Bus. & Corp. Development |
|
2015-12-16 |
4 |
D |
$7.94 |
$1,818 |
D/D |
(229) |
4,022 |
|
- |
|
Robin Sherrington |
SVP Bus. & Corp. Development |
|
2015-12-16 |
4 |
OE |
$5.22 |
$2,145 |
D/D |
411 |
4,251 |
|
- |
|
Azab Mohammad |
Director |
|
2015-12-11 |
4 |
OE |
$5.22 |
$12,888 |
D/D |
2,469 |
4,938 |
|
- |
|
Holler Frank A |
Director |
|
2015-11-24 |
4 |
D |
$9.39 |
$9,343 |
D/D |
(995) |
175,869 |
|
- |
|
Holler Frank A |
Director |
|
2015-11-24 |
4 |
OE |
$5.22 |
$10,738 |
D/D |
2,057 |
176,864 |
|
- |
|
Patou Gary |
Director |
|
2015-11-04 |
4 |
D |
$8.32 |
$16,266 |
D/D |
(1,955) |
4,086 |
|
- |
|
Patou Gary |
Director |
|
2015-11-04 |
4 |
OE |
$5.22 |
$18,254 |
D/D |
3,497 |
6,041 |
|
- |
|
Tarnow Michael M |
Director |
|
2015-11-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,041 |
55,167 |
|
- |
|
Tarnow Michael M |
Director |
|
2015-11-02 |
4 |
OE |
$5.22 |
$26,314 |
D/D |
5,041 |
60,208 |
|
- |
|
Goldberg Y. Paul |
VP of Clinical Development |
|
2015-09-24 |
4 |
S |
$8.60 |
$103,200 |
D/D |
(12,000) |
6,000 |
|
- |
|
Goldberg Y. Paul |
VP of Clinical Development |
|
2015-09-24 |
4 |
S |
$8.60 |
$103,200 |
D/D |
(12,000) |
6,000 |
|
- |
|
Goldberg Y. Paul |
VP of Clinical Development |
|
2015-09-23 |
4 |
S |
$9.02 |
$36,080 |
D/D |
(4,000) |
18,000 |
|
- |
|
Goldberg Y. Paul |
VP of Clinical Development |
|
2015-09-23 |
4 |
S |
$9.02 |
$36,080 |
D/D |
(4,000) |
18,000 |
|
- |
|
Goldberg Y. Paul |
VP of Clinical Development |
|
2015-09-22 |
4 |
S |
$9.33 |
$57,384 |
D/D |
(6,149) |
22,000 |
|
- |
|
Goldberg Y. Paul |
VP of Clinical Development |
|
2015-09-22 |
4 |
S |
$9.33 |
$57,384 |
D/D |
(6,149) |
22,000 |
|
- |
|
231 Records found
|
|
Page 8 of 10 |
|
|